AI-Powered
Pharmaceutical Intelligence
Access to drugs, clinical trials, patents, literatures and news in one search
Try:
AL-102 (Ayala)Crohn DiseasePneumococcal InfectionsFGFRL1APOC3Pfizer Inc.
109
K
Drugs & Biologics
46
K
Targets
1
M
Organizations
988
K
/
256
K
Clinical Trials / Results
69
M
Literatures
17
M
Patents
Recent blog posts
Analysis of Investment Trends and Licensing of Pharmaceuticals in the Healthcare Industry in January 2025
DrugDeal Decode
10 min read
Analysis of Investment Trends and Licensing of Pharmaceuticals in the Healthcare Industry in January 2025
24 February 2025
In January 2025, the global pharmaceutical industry's investment and licensing activities demonstrated a strong interest in novel treatment methods and technologies.
Read →
Analysis of Collaborations and Transactions in the Pharmaceutical Industry in January 2025
DrugDeal Decode
14 min read
Analysis of Collaborations and Transactions in the Pharmaceutical Industry in January 2025
24 February 2025
In January 2025, the pharmaceutical collaborations and transactions showcased a diversified trend of development, ranging from multinational pharmaceutical corporations to startup biotech enterprises.
Read →
Major Funding Rounds Drive Next-Gen Therapies in January 2025
DrugDeal Decode
14 min read
Major Funding Rounds Drive Next-Gen Therapies in January 2025
24 February 2025
With the thriving development of the biopharmaceutical industry, January 2025 witnessed several significant financing events exceeding $100 million.
Read →
Check out our latest report
Advanced Technologies and Intellectual Property Trends in ADC Research and Development

Advanced Technologies and Intellectual Property Trends in ADC Research and Development

Currently, antibody-drug conjugate (ADC) therapy is experiencing a phase of robust development. Numerous ADC drugs have received regulatory approval for market launch globally and have demonstrated significant efficacy across various tumor types. However, ADC therapy also encounters several practical challenges, such as ensuring drug stability, managing toxicity, designing clinical trials, and controlling costs. To address these challenges, researchers and pharmaceutical companies must continuously explore innovative technologies and optimize the design and manufacturing processes of ADCs to enhance both the safety and efficacy of treatment.This report offers a comprehensive analysis of the pivotal technologies and novel components associated with ADC therapy. It examines the current thriving landscape, practical challenges, and future innovations in ADC therapy. Additionally, it explores the global patent environment, including detailed patent analyses and emerging trends. Finally, the report anticipates potential future research directions for ADC therapy.

Global Drug R&D Express (Jan 2025)

Global Drug R&D Express (Jan 2025)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of January, totaling 97 drugs. Among them, 1 first-to-market drugs and 1 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Next-Gen Therapeutics for  Fat Loss and Muscle  Preservation:   Emerging Targets and  Strategies

Next-Gen Therapeutics for Fat Loss and Muscle Preservation: Emerging Targets and Strategies

The core content of this report is about the global Next-Gen therapeutics drugs for fat loss and muscle preservation. Starting from the leading antagonist of Activin (Activin) that targets the Activin-ActRII-ActRI pathway, the report elaborates on the basic information, mechanism of action, and therapy of the Activin-ActRII-ActRI pathway, and focuses on analyzing the key drugs in the ActRII pathway and other drugs for treating obesity and muscle loss syndrome. It presents a clear and comprehensive overview of the recent developments in the global research and development of new generation weight loss drugs for fat loss and muscle preservation.The summary section recommends some promising drugs and provides the reasons for the recommendations as well as possible risk factors.

Who We Serve
01
R&D Decision Makers
R&D Decision Makers
We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.
02
Business Development Professionals
Business Development Professionals
We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.
03
Pharmaceutical Analyst
Pharmaceutical Analyst
We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!
Get started for free today!
Access to drugs, clinical trials, patents, literatures and news in one search.